Iran Unveils Production Line of New Home-Made Injectable Anti-Cancer Drug

Addressing the unveiling ceremony, Dehqani Firouzabadi said the country needs nearly 400,000 doses of the drug every year that will be sufficiently met with the new production line. 

Cyclophosphamide is used to treat a wide range of cancers, including blood and ovarian cancers.

Also, Mehdi Abbasi, the head of Alborz Park of Science and Technology, which hosts the knowledge-based Nano Alvand company, underlined the positive effects of the new drug in treating a wide range of cancer types.

“This injectable anti-cancer drug is used to treat patients suffering from various types of cancer, including leukemia, ovarian, breast and eye cancer,” he said.

Abbasi underlined that by launching the production line of cyclophosphamide, the country does not need to import the drug anymore.

In a relevant development in November, a senior Iranian official had announced that the nano-based medication produced by the country’s scientists have saved over $90mln of foreign currency in the past 7 years.

“Based to our assessments, Iran has exported $9mln worth of nano drugs in the past 7 years and the sales of anti-cancer nano drugs inside the country is also estimated at 3,700 billion Rials,” Emad Ahmadvand, the head of the headquarters for the development of nanotechnology affiliated to the Iranian Vice-Presidency for Science, Technology and Knowledge-Based Economy.

He noted that the exported anti-cancer nano drugs include Sina Doxosome, Padynex, and Paclinab.

“Iran's anti-cancer nano drug products have also saved over $90mln of foreign currency in the past 7 years,” Ahmadvand said.

4155/v